Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Girish, Jayadeva"'
Autor:
Sascha Keller, Ulrich Kunz, Ulrike Schmid, Jack Beusmans, Martin Büchert, Min He, Girish Jayadeva, Christophe Le Tourneau, Doreen Luedtke, Heiko G. Niessen, Zohra Oum’hamed, Sina Pleiner, Xiaoning Wang, Ralph Graeser
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Background BI 836880 is a humanized bispecific nanobody® that binds to and blocks vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2). A comprehensive biomarker and modeling approach is presented here that supported dose fi
Externí odkaz:
https://doaj.org/article/e16d3e8186014e00ab772fd03b57d4cc
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 13, Iss 1, Pp 237-244 (2017)
In 2010, porcine circovirus type 1 (PCV1) material was unexpectedly detected in the oral live-attenuated human rotavirus (RV) vaccine, Rotarix™ (GSK Vaccines, Belgium). An initial study (NCT01511133) found no immunologic response against PCV1 in 40
Externí odkaz:
https://doaj.org/article/f04090e835134f7aa042602bbce8a969
Autor:
Karl-Heinz Liesenfeld, John Mondick, William Knebel, Jia Kang, Rena J. Eudy-Byrne, Girish Jayadeva
Publikováno v:
British Journal of Clinical Pharmacology
Aims Adalimumab-adbm is a monoclonal antibody developed as a biosimilar to adalimumab (Humira, AbbVie Inc.). The key objectives of this study were using a population pharmacokinetic (PPK) approach to assess pharmacokinetic (PK) similarity between ada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a439f0509498a490010971c1a6ac90be
https://doi.org/10.1111/bcp.14330
https://doi.org/10.1111/bcp.14330
Autor:
Girish Jayadeva, Alan Menter, Sigrid Balser, Ashley Cauthen, Stefan Beissert, Peter Weisenseel, Petr Arenberger, Sasha Jazayeri, Niklas Czeloth, Jennifer Soung
Publikováno v:
Expert opinion on biological therapy. 21(1)
Background: BI 695501 is an approved biosimilar to Humira® reference product (RP).Research design and methods: In this randomized Phase III trial (VOLTAIRE-PSO), patients with moderate-to-severe ch...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e28ec3230437cc99026357a92735927
https://pubmed.ncbi.nlm.nih.gov/33317345
https://pubmed.ncbi.nlm.nih.gov/33317345
Autor:
Tim Meyer, Evgeny Ledin, Dong-Wan Kim, François Ghiringhelli, Piotr Serwatowski, Mark Voskoboynik, Harald Timotheus Landsteiner, Victoria Chen, Girish Jayadeva, Teresa Macarulla
Publikováno v:
Journal of Clinical Oncology. 40:434-434
434 Background: Combination of anti-VEGF compounds and immune checkpoint inhibitors is an approved therapy across multiple solid tumors, including advanced HCC. This phase Ib study (NCT03468426) is assessing BI 836880 (bispecific VEGF/Ang2 nanobody)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f01c314c03dfb51e8b8a13ff66c194fc
https://doi.org/10.1200/jco.2022.40.4_suppl.434
https://doi.org/10.1200/jco.2022.40.4_suppl.434
Autor:
Thijs van Iersel, Bernd Liedert, Steven Ramael, Ivo Sonderegger, Viktoria Moschetti, Benjamin Van Hoorick, Renger Tiessen, Sabrina Wiebe, Girish Jayadeva, Benjamin Lang
Publikováno v:
Rheumatology and Therapy. 5:403-421
BI 695501 has shown similar efficacy, safety, and immunogenicity to the adalimumab reference product, Humira®. We present two phase 1 studies comparing the pharmacokinetics, safety, and immunogenicity of BI 695501 delivered via autoinjector (AI) vs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8785abbbded17f06e957ac28a2cb6cfc
https://doi.org/10.1007/s40744-018-0119-1
https://doi.org/10.1007/s40744-018-0119-1
Autor:
Jong Seok Lee, François Ghiringhelli, E. Ledin, David Berz, Mark Voskoboynik, Dai Woo Kim, Nicolas Girard, C. Mascaux, Martin Wermke, Jaafar Bennouna, Arnaud Jeanson, Piotr Serwatowski, Enriqueta Felip, Björn Hackanson, Thierry Lesimple, Victoria Chen, Girish Jayadeva, Jürgen Alt, Harald Timotheus Landsteiner, Michael C. Burger
Publikováno v:
Annals of Oncology. 32:S597
Background: Combining anti-VEGF/Ang2 and anti-PD-1 therapy promotes an immunopermissive state, supportive of T-cell-mediated tumour cell destruction. This phase Ib study is assessing BI 836880 plus ezabenlimab in patients (pts) with advanced solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a971eca64ae1d62a1ed2ab18c347d461
https://doi.org/10.1016/j.annonc.2021.08.1054
https://doi.org/10.1016/j.annonc.2021.08.1054
Autor:
Harald Timotheus Landsteiner, Dong Wan Kim, Martin Wermke, François Ghiringhelli, Jong Seok Lee, Nicolas Girard, Victoria Chen, Girish Jayadeva, Fabrice Barlesi, Björn Hackanson, David Berz, Thierry Lesimple, Jaafar Bennouna, Enriqueta Felip, Jürgen Alt
Publikováno v:
Annals of Oncology. 32:S325
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c31ef0b092e2ad644b2171550c65badf
https://doi.org/10.1016/j.annonc.2021.05.550
https://doi.org/10.1016/j.annonc.2021.05.550
Publikováno v:
Expert opinion on biological therapy. 19(10)
Objective: To evaluate long-term safety, efficacy, and immunogenicity of BI 695501 in patients with moderately-to-severely active rheumatoid arthritis (RA) who have completed VOLTAIRE-RA. Methods: Eligible patients for this phase 3b open-label extens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::334bb766959d9d29193d3d475fb0018e
https://pubmed.ncbi.nlm.nih.gov/31387417
https://pubmed.ncbi.nlm.nih.gov/31387417
Autor:
Harald Timotheus Landsteiner, Jong Seok Lee, Victoria Chen, Nicolas Girard, Céline Mascaux, Arnaud Jeanson, Bjoern Hackanson, Juergen Alt, Michael C. Burger, Dong Wan Kim, Girish Jayadeva, Piotr Serwatowski, François Ghiringhelli, Fabrice Barlesi, David Berz, Thierry Lesimple, Mark Voskoboynik, Jaafar Bennouna, Martin Wermke, Enriqueta Felip
Publikováno v:
Journal of Clinical Oncology. 39:2579-2579
2579 Background: In preclinical studies, the combination of anti-VEGF/Ang2 and anti-PD-1 therapy has been shown to promote an immunopermissive state, which is supportive of T-cell-mediated tumor cell destruction. BI 836880 is a humanized bispecific n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::407c9f8c50b1af2403d0c967ebf86814
https://doi.org/10.1200/jco.2021.39.15_suppl.2579
https://doi.org/10.1200/jco.2021.39.15_suppl.2579